Extended Data Fig. 4: Antitumour ability of the Allo-NCAP vaccine.
From: Autophagosomes coated in situ with nanodots act as personalized cancer vaccines
a, Schematic illustration of the preparations of Con-AP by increasing the pH in lysosome in vitro, and the Allo-NCAPs by Ti2NX nanodots in vitro. b, Tumour growth curves after different treatments in the 4T1 tumour model. n = 7. P = 7 × 10−14. c, Survival curves of mice after various treatments. d, Individual tumour growth curves of the PBS, Con-AP, and Allo-NCAP groups after treatment; n = 7 mice per group. e, Schematic illustration of the experimental design with the luc-4T1 hematogenous metastasis model. f, In vivo bioluminescence imaging of 4T1-luc pulmonary metastases. g, Average tumour burden (photons/second; p/s) of each group on day 17; n = 4 mice per group. h, Inflammatory cytokines in the serum were detected using an ELISA kit. i, Photographs of lung and H&E-stained lung sections (metastatic tumour area, white dash) on day 22. j, Images of lung sections after staining with CD206 and GzmB antibodies and DAPI, CD206 (red) and GzmB (green). The experiments were repeated three times. Scale bar, 50 μm. Error bars represent the mean ± s.d. The data in (b) were analysed by two-way ANOVA, and the data in (g) were analysed by two-tailed Student’s t test.
